Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Fed Taper Smoke and Mirrors - 5th May 21
Global Economic Recovery 2021 and the Dark Legacies of Smoot-Hawley - 5th May 21
Utility Stocks Continue To Rally – Sending A Warning Signal Yet? - 5th May 21
ROIMAX Trading Platform Review - 5th May 21
Gas and Electricity Price Trends so far in 2021 for the United Kingdom - 5th May 21
Crypto Bubble Mania Free Money GPU Mining With NiceHash Continues... - 4th May 21
Stock Market SPX Short-term Correction - 4th May 21
Gold & Silver Wait Their Turn to Ride the Inflationary Wave - 4th May 21
Gold Can’t Wait to Fall – Even Without USDX’s Help - 4th May 21
Stock Market Investor Psychology: Here are 2 Rare Traits Now on Display - 4th May 21
Sheffield Peoples Referendum May 6th Local Elections 2021 - Vote for Committee Decision's or Dictatorship - 4th May 21
AlphaLive Brings Out Latest Trading App for Android - 4th May 21
India Covid-19 Apocalypse Heralds Catastrophe for Pakistan & Bangladesh, Covid in Italy August 2019! - 3rd May 21
Why Ryzen PBO Overclock is Better than ALL Core Under Volting - 5950x, 5900x, 5800x, 5600x Despite Benchmarks - 3rd May 21
MMT: Medieval Monetary Theory - 3rd May 21
Magical Flowering Budgies Bird of Paradise Indoor Grape Vine Flying Fun in VR 3D 180 UK - 3rd May 21
Last Chance to GET FREE Money Crypto Mining with Your Desktop PC - 2nd May 21
Will Powell Lull Gold Bulls to Sweet Sleep? - 2nd May 21
Stock Market Enough Consolidation Already! - 2nd May 21
Inflation or Deflation? (Not a silly question…) - 2nd May 21
What Are The Requirements For Applying For A Payday Loan Online? - 2nd May 21
How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part1 - 1st May 21
INDIA COVID APOCALYPSE - 1st May 21
Are Technicals Pointing to New Gold Price Rally? - 1st May 21
US Dollar Index: Subtle Changes, Remarkable Outcomes - 1st May 21
Stock Market Correction Time Window - 30th Apr 21
Stock Market "Fastest Jump Since 2007": How Leveraged Investors are Courting "Doom" - 30th Apr 21
Three Reasons Why Waiting for "Cheaper Silver" Doesn't Make Cents - 30th Apr 21
Want To Invest In US Real Estate Market But Don’t Have The Down Payment? - 30th Apr 21
King Zuckerberg Tech Companies to Set up their own Governments! - 29th Apr 21
Silver Price Enters Acceleration Phase - 29th Apr 21
Financial Stocks Sector Appears Ready To Run Higher - 29th Apr 21
Stock Market Leverage Reaches New All-Time Highs As The Excess Phase Rally Continues - 29th Apr 21
Get Ready for the Fourth U.S. Central Bank - 29th Apr 21
Gold Mining Stock: Were Upswings Just an Exhausting Sprint? - 29th Apr 21
AI Tech Stocks Lead the Bull Market Charge - 28th Apr 21
AMD Ryzen Overclocking Guide - 5900x, 5950x, 5600x PPT, TDC, EDC, How to Best Settings Beyond PBO - 28th Apr 21
Stocks Bear Market / Crash Indicator - 28th Apr 21
No Upsetting the Apple Cart in Stocks or Gold - 28th Apr 21
Is The Covaids Insanity Actually Getting Worse? - 28th Apr 21
Dogecoin to the Moon! The Signs are Everywhere, but few will Heed them - 28th Apr 21
SPX Indicators Flashing Stock Market Caution - 28th Apr 21
Gold Prices – Don’t Get Too Excited - 28th Apr 21
6 Challenges Contract Managers Face When Handling Contractual Agreements - 28th Apr 21
Corsair H150i Pro iCUE Firmware Update Says Bye Bye - H100i, H115i, Bricked Jet Engine Fans Fix - 27th Apr 21
Bude Cliff Walk and Secluded Pebble Beach Tour in VR 360 - Cornwall UK Holidays 2021 - 27th Apr 21
The Top 3 CBD Oils with Anti-Inflammatory Properties for Stopping Pain - 27th Apr 21 -
Biden’s Green New Deal - 27th Apr 21
Gold Stocks Upleg Accelerates - 27th Apr 21
The Tax Plan to Slay the Stocks Bull Market? - 26th Apr 21
See What’s Next for European Markets - 26th Apr 21
Gold's Perfect Storm - 26th Apr 21
Biden’s ‘Green Reset’ Could Be Great for Silver - 26th Apr 21
SPX Stock Market Short Squeeze – Here Or Not? - 25th Apr 21
Fiscal Guilt: What a Shift in Monetary Policy Portends for Investors - 25th Apr 21
Gold Price Reversal? Have No Fear! - 24th Apr 21
No Fear Of Inflation; Threat Of Deflation - 24th Apr 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Fighting Cancer Ourselves

Companies / Healthcare Sector Jul 29, 2011 - 02:19 AM GMT

By: Casey_Research

Companies

Best Financial Markets Analysis ArticleChris Wood, Casey Extraordinary Technology writes: Worldwide, tens of thousands of researchers are working feverishly on a cure for cancer, testing countless new drugs and dozens of novel approaches. Most will end up in the dustbin. But among the most promising of that small group likely to make it to market is a new type of monoclonal antibody therapy.


That may sound like a daunting scientific concept to try to wrap one’s head around, but in essence monoclonal antibodies are simple. Most of us are familiar with antibodies, the road warriors of the human body’s immune system. They’re those little Y-shaped proteins that are used to identify and neutralize foreign objects in the body (like bacteria and viruses) by binding themselves to the target – called an antigen – and killing it.

Although one antibody is generally very similar to another in structure, a small region at the tip of the protein is extremely variable – enough so that there are millions of distinct antibodies with slightly different tip structures, or antigen binding sites. This diversity allows the immune system both to recognize an equally wide variety of antigens and to come up with new responses to new types of infections.

Now, what if the body’s ability to construct antigen-specific antibodies could be harnessed in the lab? What if scientists could produce substantial amounts of a single antibody (whichever one they wanted for a particular antigen) and that antibody alone, outside of the body? What if our own capacity for fighting infection could be turned against cancer cells? Wouldn’t that be better than present chemotherapies, which willy-nilly blast diseased and healthy cells alike?

Of course it would. Making it happen is another matter.

Fortunately, many of the technical issues were resolved about 35 years ago, when Cesar Milstein, Georges Kohler, and Niels Jerne discovered how to fuse an antibody-producing cell with a cancer cell in the lab – an effort that won them the 1984 Nobel Prize in Physiology. The resulting mutant – dubbed a hybridoma – will produce large amounts of identical antibodies from a unique parent (that’s the “monoclone” part) essentially forever.

The remaining challenge was how to put monoclonal antibodies to work against cancer.

What researchers came up with was elegant: To borrow from military parlance, they would create a “smart bomb,” an antibody which – when combined with a cancer-killing drug – would detonate inside the diseased cell.

Though elementary in conception, the smart bomb was a long time in coming. First, an antibody had to be developed that would be accepted by the host and would navigate the bloodstream until it linked to a particular cancer cell. Then there would have to be a means for a potent cancer drug to be locked to it in such a way that the bond wouldn’t disintegrate along the way; such a failure would create havoc among healthy cells. Finally, the antibody would have to be able to release its piggybacked drug once it reached its target.

The payoff is huge. Not only does this form of therapy allow for much more precise targeting, it permits the use of cytotoxins (cancer-killing agents) that are 100 to 1,000 times more potent than traditional chemotherapy drugs – a toxicity that would cause far too much collateral damage if they were introduced into the body in a non-specific way.

Fighting cancer with our own built-in defense mechanisms sounds both logical and at the same time improbable, since up to now we’ve had such little luck in combating the disease ourselves.

Yet that’s the promise of this new monoclonal antibody therapy, and the good news is that today it is far down in the research pipeline. Much testing in human subjects has been done, with results among patients whose cancers were previously deemed intractable that are nothing short of spectacular.

FDA clearance has been fast-tracked. The therapy has already been granted approval at the subcommittee level, with the full agency set to rule by the end of August. The first monoclonal antibodies with novel linkage systems binding to potent cytotoxins could hit the market this year, saving lives and making fortunes for both the company that developed them and those who invested in it.

Even the most diligent investor can’t keep up with all the developments in cancer research, let alone build the knowledge necessary to understand both the promises and challenges they face. That’s what makes a subscription to Casey Extraordinary Technology invaluable; the technology team does that work. And they’ve put together a curing cancer portfolio so that you can get in on the best prospects.

© 2011 Copyright Casey Research - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in